Stoke Therapeutics (STOK) Cash & Equivalents (2018 - 2026)

Stoke Therapeutics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $155.7 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 43.36% year-over-year to $155.7 million in Q1 2026; TTM through Mar 2026 was $155.7 million, a 43.36% decrease from a year earlier, with the FY2025 full-year figure at $84.2 million, down 34.19% from the prior year.
• Cash & Equivalents advanced to $155.7 million in Q1 2026 per STOK's latest filing, from $84.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $274.8 million in Q1 2025 and bottomed at $67.8 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $150.0 million (2024), against an average of $146.6 million.
• Across the five-year window, Cash & Equivalents slumped 68.56% in 2022 and soared 183.47% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $113.6 million in 2022, then soared by 68.59% to $191.4 million in 2023, then slumped by 33.15% to $128.0 million in 2024, then tumbled by 34.19% to $84.2 million in 2025, then surged by 84.82% to $155.7 million in 2026.
• Per Business Quant, the three latest STOK Cash & Equivalents figures stand at $155.7 million (Q1 2026), $84.2 million (Q4 2025), and $83.4 million (Q3 2025).